Sanofi (SNY) Q2 2024 Earnings Call Transcript
Sanofi (NASDAQ:SNY ) Q2 2024 Q2 2024 Earnings Conference Call July 25, 2024 8:30 AM ET Company Participants Thomas Kudsk - Investor Relations Paul Hudson - Chief Executive Officer François Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian - Executive Vice President, Head of Research and Development Brian Foard - Executive Vice President & Head-Specialty Care, Sanofi Thomas Triomphe - Executive Vice President-Vaccines, Sanofi Olivier Charmeil - Executive Vice President, Vaccines Conference Call Participants Graham Parry - BofA Shirley Chang - Barclays Seamus Fernandez - Guggenheim Jo Walton - UBS Tim Anderson - Wolfe Research Luisa Hector - Berenberg Florent Cespedes - Bernstein David Risinger - Leerink Gary Steventon - Exane Ben Jackson - Jefferies Eric Berrigaud - Stifel Peter Verdult - Citi Thomas Kudsk This is Thomas Kudsk Larsen with the IR team. Welcome to the Q2 2024 Conference Call for investors and analyst.
Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised
Sanofi (SNY) posts mixed quarterly results, beating estimates for earnings while missing the same for sales. It raises its 2024 earnings growth expectations at CER.
Sanofi bumps up full-year forecast after strong Q2 profit
Sanofi's second-quarter profit rose 3.2% on strong demand for its blockbuster asthma drug Dupixent and better-than-expected sales of new launches, with the company now expecting a stable full-year profit compared to a prior forecast of a fall.
Sanofi to invest $437 mln in India global centre, double its workforce
French drugmaker Sanofi plans to invest 400 million euros ($437.24 million) in its global capacity centre (GCC) in India by the end of the decade, as it aims to expand and more than double its workforce over the next two years, a top company executive said on Wednesday.
Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug
Shares of Kymera Therapeutics (KYMR) jumped Tuesday, a day after it said partner Sanofi (SNY) agreed to extend a Phase 2 trial of its experimental drug to treat certain autoimmune skin diseases.
Bpifrance eyes investment in Sanofi's consumer health business
Bpifrance Executive Director Jose Gonzalo said that the public investment bank is considering a potential investment in Sanofi's consumer health unit, Bloomberg News reported on Thursday.
EU approves Sanofi's Dupixent for 'smoker's lungs'
Sanofi and partner Regeneron on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a chronic lung disease, a rare case of the EU clearing a drug faster than the United States.
Sanofi eyes German insulin investment of up to $1.6 bln, source says
French drugmaker Sanofi is nearing a decision to invest between 1.3 billion and 1.5 billion euros ($1.4-$1.6 billion) to upgrade its production of long-acting insulin shots in Germany, a person familiar with the plan told Reuters on Monday.
Sanofi eyes investment of up to $1.6 bln in Germany, Handelsblatt says
French drugmaker Sanofi is nearing a decision to invest between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) at a major production site in Frankfurt, Germany, where it makes insulin brand Lantus, newspaper Handelsblatt reported on Monday.
Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition
VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26. SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from SNY/REGN and GSK. Verona has the potential for further growth beyond the current approval, although in the near-term, initial sales seem likely to be a major determinant of the stock's direction.
German vaccine panel endorses Astra-Sanofi's RSV shot for infants
Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infection RSV.
Sanofi-backed Formation Bio raises $372 million in late-stage funding round
AI-based drug developer Formation Bio said on Wednesday that it has raised $372 million in a late-stage funding round, with a significant participation from French drugmaker Sanofi.
